Response to 'Early initiation of dialysis via percutaneous catheters'
Kidney International (2010) 77, 367; doi:10.1038/ki. 2009.446 In this issue of Kidney International, Hirsch 1 has quite rightly drawn attention to the adverse consequences of excess percutaneous catheter use as the initial method of vascular access in patients who are newly started on hemodialysis. He also adds such catheter use to the list of 'rising tides' in dialysis therapy, as a supplement to our mini-review regarding the increasing frequency of 'early start' of dialysis. 2 Precisely how the secular trends of 'early start' and 'catheter first' interact is not clear. The issue of catheter use in 'early' and 'late' start of hemodialysis is currently under study. Preliminary data from Canada indicate that the prevalence of catheter use is not different between those starting dialysis at high levels of estimated glomerular filtration rate (eGFR), 410 ml/min per 1.73 m 2 , and those starting dialysis at lower levels of eGFR, o10 ml/min per 1.73 m 2 (WF Clark, personal communication). It is very likely that catheter use contributes to the mortality and morbidity of patients treated with hemodialysis, via the adverse consequences of infection and inflammation. At present, we have no clear indication that 'early start' of hemodialysis is uniquely associated with an excess of catheter usage, nor can we be certain that the excess mortality associated with 'early start' is directly the consequence of the 'early start' itself or is explained by concomitant demographic or co-morbidity factors. What is certain is that there is a 'rising tide' of both 'early start' and 'catheter first' strategies selected by treating physicians and their patients. We need to better understand the magnitude and nature of the adverse consequences of these choices. We continue to believe that the 'early start' of dialysis (at eGFR 410 ml/min per 1.73m 2 ), regardless of the access method chosen, is not justified, except when compelling evidence of the need for dialysis therapy in Stage 5 chronic kidney disease is present (for example, volume overload or congestive heart failure refractory to diuretic therapy, pericarditis, severe acidosis, and unmanageable hyperkalemia).
